What is a pharma giant to do when sales are being lost to new generic versions of its meds? Let's make a deal! And Pfizer is leading the way, with 51 mergers and/or acquisitions in 2010, followed
quickly by Sanofi-Aventis and Novartis.
The biomedical data tracker Life Science Analytics reports that pharmaceutical deals as of October were up 20% over the same period last year. Top
areas for dealmakers were cancer treatments, 24%; infectious diseases, 18%, and central nervous system medicines, 14%.
The most noteworthy change in the line-up of dealmakers was
Sanofi-Aventis' move from 14th on the list last year to second this year.
Read the whole story at The [New London, Conn.] Day »